VACCINEX INC (VCNX) Stock News

NASDAQ:VCNX - US9186403013 - Common Stock

1.41 USD

-2.24 (-61.37%)

Last: 12/17/2024, 9:35:36 PM

1.3211 USD

-0.09 (-6.3%)

After Hours: 12/17/2024, 9:35:36 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VCNX Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: Vaccinex, Inc.

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

3 months ago - By: Vaccinex, Inc.

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

4 months ago - By: Vaccinex, Inc.

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

8 months ago - By: Benzinga - Mentions: TNXP OPTX PRTG DBGI ...

Dow Dips Over 200 Points; US Retail Sales Top Estimates

a year ago - By: BusinessInsider

News Image

VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024

a year ago - By: InvestorPlace

VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024

4 months ago - By: Vaccinex, Inc.

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

6 months ago - By: Vaccinex, Inc.

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

6 months ago - By: Vaccinex, Inc.

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

8 months ago - By: Benzinga - Mentions: CAMP LMAT TEVA TNXP ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

8 months ago - By: Vaccinex, Inc.

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

8 months ago - By: Vaccinex, Inc.

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

9 months ago - By: Vaccinex, Inc.

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

9 months ago - By: Vaccinex, Inc.

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

10 months ago - By: Vaccinex, Inc.

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

10 months ago - By: Vaccinex, Inc.

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

10 months ago - By: Vaccinex, Inc.

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

10 months ago - By: Vaccinex, Inc.

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

10 months ago - By: Vaccinex, Inc.

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

10 months ago - By: Vaccinex, Inc.

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

10 months ago - By: Vaccinex, Inc.

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

10 months ago - By: Vaccinex, Inc.

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

a year ago - By: Vaccinex, Inc.

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

a year ago - By: Vaccinex, Inc.

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

a year ago - By: Vaccinex, Inc.

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

a year ago - By: Vaccinex, Inc.

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

a year ago - By: InvestorPlace - Mentions: ADGM AGBA AKAN CONN ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

a year ago - By: Vaccinex, Inc.

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

a year ago - By: Vaccinex, Inc.

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

a year ago - By: InvestorPlace - Mentions: YIBO LIPO CGTX TIVC ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

a year ago - By: Vaccinex, Inc.

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024